Showing 511-520 of 1066 results for "".
- Business Advisorhttps://practicalneurology.com/columns/practice-management/business-advisor/31437/Navigating Prescription Costs and Generic Substitutions in Epilepsy ManagementThe escalating costs of prescription medications present significant challenges for epilepsy patients, exacerbated by rising insurance premiums, increased co-pays, and higher deductibles. These financial strains often forc
- Expert Opinionhttps://practicalneurology.com/columns/practice-management/expert-opinion/31428/Understanding Eyelid Myokymia: A Benign Neurological PhenomenonEyelid myokymia, characterized by intermittent, fine, involuntary contractions of the eyelid muscles, is a condition frequently encountered in clinical neurology. Typically unilateral and localized to the lower eyelid, it presents as twi
- News Briefshttps://practicalneurology.com/columns/practice-management/news-briefs/31285/Recent Advances and Insights in Neurology: August 2006Neurology continues to evolve with significant breakthroughs and research findings presented in recent studies and conferences. A notable development from the Aging Research Center at Karolinska Institutet introduces a predictive model for dement
- Bracing for the Medicare Shockwavehttps://practicalneurology.com/columns/practice-management/bracing-for-the-medicare-shockwave/31365/Impact of 2006 Medicare Reforms on Neurological Practice and Patient CareThe evolving landscape of Medicare in 2006 presents significant challenges and opportunities for neurologists and healthcare professionals. Recent adjustments in Medicare reimbursement rates have introduced uncertainty followin
- Are We Missing the Connection Between Headache and Fibromyalgia?https://practicalneurology.com/diseases-diagnoses/headache-pain/PN0805CvrFeature-pdf/31413/Dr. Robert L. Knobler’s August 2005 article in *Practical Neurology* critically examines the diagnosis of fibromyalgia syndrome (FMS) and its broader implications for understanding migraines and chronic pain in clinical practice. Knobler highlights the pervasive disregard and overdiagnosis of FMS, o
- Will the Medical Liability Crisis Hammer Your Practice?https://practicalneurology.com/archives/2005-june/PN0605malpractice-pdf/31441/Medical Malpractice Reform: Navigating the Ongoing Liability CrisisMedical malpractice reform remains a critical yet contentious issue within the healthcare sector, as highlighted in the June 2005 issue of *Practical Neurology*. Despite sustained advocacy by physicians, national progress on liabilit
- 10 Tips for Managing Adolescent Epilepsyhttps://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/pn0308-epilepsy-fea-pdf/31041/Managing Epilepsy in Adolescents: Addressing Unique Challenges for Optimal OutcomesEpilepsy management in adolescents presents distinct challenges that transcend typical age-related barriers, necessitating tailored approaches for effective treatment. As highlighted in the March 2008 issue of *Practi
- Will Generics Gobble Up The Neurology Market?https://practicalneurology.com/columns/practice-management/will-generics-gobble-up-the-neurology-market/31082/Generics Gain Ground in Neurology: Implications for Clinical PracticeThe landscape of neurology pharmacotherapy is shifting as generic medications increasingly replace brand-name drugs, promising substantial cost savings without compromising efficacy. As highlighted in the December 2007 issue of *Pr
- Pain Managementhttps://practicalneurology.com/diseases-diagnoses/headache-pain/pn1107painmanagement-pdf/31103/Defining Neuropathic Pain: Challenges and Screening Tools for Clinical PracticeNeuropathic pain, a pivotal element in the pathophysiology of chronic pain, remains challenging to define and diagnose accurately. This complexity arises from its dual presentation of positive symptoms, such as burning pa
- Vascular Clinichttps://practicalneurology.com/columns/practice-management/vascular-clinic/31171/Thrombolytic therapy for acute ischemic stroke, specifically tissue plasminogen activator (tPA), remains significantly underutilized, with treatment rates persisting below five percent despite robust evidence supporting its efficacy and safety. Since the FDA approved tPA for stroke in 1996, multiple